Compare Bank of Montreal (BMO) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs Incyte Corporation — how do they compare? Bank of Montreal trades at $182.04 (market cap $126.83B), while Incyte Corporation trades at $120.45 (market cap $24.54B). The key difference: Bank of Montreal is far larger — about 5.2× Incyte Corporation's market cap, and Bank of Montreal pays a 2.69% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| BMO | INCY | |
|---|---|---|
Market Cap | $126.83B | $24.54B |
Sector | Financials | Health |
52-Week High | $183.65 | $129.93 |
52-Week Low | $112.54 | $81.61 |
Dividend Yield | 2.69% | — |
Enterprise Value | — | $20.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
